VistaGen Therapeutics, Inc.
VTGN
$0.61
-$0.02-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.49% | 40.98% | 190.48% | -107.61% | -43.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.49% | 40.98% | 190.48% | -107.61% | -43.07% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 29.49% | 40.98% | 190.48% | -107.61% | -43.07% |
| SG&A Expenses | 38.95% | 4.79% | -4.31% | 3.71% | 7.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.28% | 40.95% | 31.38% | 25.30% | 85.10% |
| Operating Income | -29.27% | -40.95% | -30.28% | -27.61% | -91.78% |
| Income Before Tax | -34.14% | -49.89% | -40.64% | -43.22% | -121.87% |
| Income Tax Expenses | -- | -- | -- | -100.00% | -- |
| Earnings from Continuing Operations | -34.14% | -49.81% | -40.64% | -43.21% | -121.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.14% | -49.81% | -40.64% | -43.21% | -121.87% |
| EBIT | -29.27% | -40.95% | -30.28% | -27.61% | -91.78% |
| EBITDA | -29.25% | -40.94% | -30.31% | -27.63% | -92.04% |
| EPS Basic | 2.44% | -28.36% | -34.79% | -38.46% | -112.26% |
| Normalized Basic EPS | 2.44% | -28.45% | -34.81% | -38.53% | -112.37% |
| EPS Diluted | 2.44% | -28.36% | -34.79% | -38.46% | -112.26% |
| Normalized Diluted EPS | 2.44% | -28.45% | -34.81% | -38.53% | -112.37% |
| Average Basic Shares Outstanding | 37.52% | 16.70% | 4.34% | 3.41% | 4.50% |
| Average Diluted Shares Outstanding | 37.52% | 16.70% | 4.34% | 3.41% | 4.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |